Semin Liver Dis 2003; 23(1): 089-100
DOI: 10.1055/s-2003-37591
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Management of Patients with Decompensated HBV Cirrhosis

Robert J. Fontana
  • Assistant Professor of Medicine, Division of Gastroenterology, University of Michigan Medical School, Ann Arbor, Michigan
Further Information

Publication History

Publication Date:
03 March 2003 (online)

ABSTRACT

Patients with decompensated hepatitis B virus (HBV) cirrhosis have a poor prognosis due to the development of progressive liver failure and hepatocellular carcinoma. Lamivudine appears to be a safe and effective antiviral agent, which may improve or stabilize liver disease in selected patients with advanced cirrhosis and active HBV replication. However, viral resistance can develop with prolonged treatment and some patients with advanced cirrhosis may not experience any discernible benefit. The use of hepatitis B immunoglobulin prophylaxis with or without lamivudine has resulted in excellent survival and a low rate of graft reinfection in patients who undergo liver transplantation for decompensated HBV cirrhosis. Adefovir and entecavir are newer antiviral agents that have activity against both wild-type and lamivudine-resistant HBV. Additional studies of individual or combination antiviral agents are urgently needed to improve further the prospects for the large number of patients worldwide with decompensated HBV cirrhosis.

REFERENCES

  • 1 Mast E E, Alter M J, Margolis H S. Strategies to prevent and control hepatitis B and C virus infections: a global perspective.  Vaccine . 1999;  17 1730-1733
  • 2 McQuillan G M, Coleman P J, Kruszon-Moran D. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition examination surveys, 1976 through 1994.  Am J Public Health . 1999;  89 14-18
  • 3 Margolis H S, Alter M J, Hadler S C. Hepatitis B: evolving epidemiology and implications for control.  Semin Liver Dis . 1991;  11 84-92
  • 4 Samuel D, Muller R, Alexander G. Liver transplantation in European patients with hepatitis B surface antigen.  N Engl J Med . 1993;  329 1842-1847
  • 5 Weissberg J I, Andres L L, Smith C I. Survival in chronic hepatitis B. An analysis of 379 patients.  Ann Intern Med . 1984;  101 613-616
  • 6 De Jongh E F, Janssen H L, De Man A R. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver.  Gastroenterology . 1992;  103 1630-1635
  • 7 Fattovich G, Brollo L, Giustina G. Natural history and prognostic factors for chronic hepatitis B.  Gut . 1991;  32 294-298
  • 8 Liaw Y F, Tai D I, Chu C M, Chen T J. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study.  Hepatology . 1988;  8 493-496
  • 9 Liaw Y F, Lin D Y, Chen T J. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study.  Liver . 1989;  9 235-241
  • 10 Donato F, Tagger A, Chiesa R. Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy.  Hepatology . 1997;  26 579-584
  • 11 Nalpas B, Berthelot P, Thiers V. Hepatitis B virus multiplication in the absence of usual serological markers: a study of 146 chronic alcoholics.  J Hepatol . 1985;  1 89-97
  • 12 Krogsgaard K, Lindhardt B O, Nielsen J O. The influence of HTLV-III infection on the natural history of hepatitis B virus infection in male homosexual HBsAg carriers.  Hepatology . 1987;  7 37-41
  • 13 Rustgi V K, Hoofnagle J H, Gerin J L. Hepatitis B virus infection in the acquired immunodeficiency syndrome.  Ann Intern Med . 1984;  101 795-797
  • 14 Liaw Y F. Role of hepatitis C virus in dual and triple hepatitis virus infection.  Hepatology . 1995;  22 1101-1108
  • 15 Benvegnu L, Fattovich G, Noventa F. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis: a prospective study.  Cancer . 1994;  74 2242-2248
  • 16 Fattovich G, Giustain G, Christensen E. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B.  Gut . 2000;  46 420-426
  • 17 Sagnelli E, Piccinino F, Pasquale F. Delta agent infection: an unfavorable event in HBsAg positive chronic hepatitis.  Liver . 1984;  4 170-176
  • 18 Tur-Kaspa R, Shaul Y, Moore D D. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer.  Virology . 1988;  167 630-633
  • 19 McMillan J S, Shaw T, Angus P W, Locarnini S A. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro.  Hepatology . 1995;  22 36-43
  • 20 Hoofnagle J H, Dusheiko G M, Schafer D F. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy.  Ann Intern Med . 1982;  96 447-449
  • 21 Ahmed A, Keeffe E B. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection.  Am J Gastroenterol . 1999;  94 249-251
  • 22 Lau G K, He M L, Fong D YT. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation.  Hepatology . 2002;  36 702-709
  • 23 Beasley R P. Hepatitis B virus. The major etiology of hepatocellular carcinoma.  Cancer . 1988;  61 1942-1956
  • 24 Yang H I, Lu S N, Liaw Y F. Hepatitis B e antigen and the risk of hepatocellular carcinoma N Engl J Med .  2002;  347 168-174
  • 25 Dragosics B, Ferenci P, Hitchman E, Denk H. Long-term follow-up study of asymptomatic HBsAg-positive voluntary blood donors in Austria: a clinical and histological evaluation in 242 cases.  Hepatology . 1987;  7 302-306
  • 26 Villeneuve J P, Desrochers M, Infante-Rivard C I. A long-term follow-up study of asymptomatic hepatitis B surface antigen positive carriers in Montreal.  Gastroenterology . 1994;  106 1000-1005
  • 27 Kamath P S, Wiesner R H, Malinchoc M. A model to predict survival in patients with end-stage liver disease.  Hepatology . 2001;  33 464-470
  • 28 Keeffe E B. Liver transplantation: current status and novel approaches to liver replacement.  Gastroenterology . 2001;  120 749-762
  • 29 Seaberg E C, Belle S H, Beringer K C, Schivins J L, Detre K M. Liver transplantation in the United States from 1987-998: updated results from the PITT-UNOS liver transplant registry. In: Cecka JM, Terasaki PI, eds. Clinical Transplants 1998 Los Angeles: UCLA Tissue Typing Laboratory 1999: 17-37
  • 30 Fattovich G, Guistina G, Schalm S W. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B.  Hepatology . 1995;  21 77-82
  • 31 Lok A SF, McMahon B J. Chronic hepatitis B.  Hepatology . 2001;  34 1225-1241
  • 32 Keeffe E B. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases?.  Am J Gastroenterol . 1995;  90 201-205
  • 33 Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep . 1996;  45 1-30
  • 34 Patel P, Voigt M D. Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States.  Am J Gastroenterol . 2002;  97 1198-1203
  • 35 Teran J C, Imperiale T F, Mullen K D, Tavill A S, McCullough A J. Primary prophylaxis of variceal bleeding in cirrhotics: a cost effectiveness analysis.  Gastroenterology . 1997;  112 473-482
  • 36 Sharara A I, Rockey D C. Gastroesophageal variceal hemorrhage.  N Engl J Med . 2001;  345 669-680
  • 37 Lucas A, D'Amico G, Galla R. TIPS for prevention of recurrent bleeding in patients with cirrhosis: meta-analysis of randomized controlled trials.  Radiology . 1999;  212 411-421
  • 38 Rossle M, Ochs A, Gulberg V. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites.  N Engl J Med . 2000;  342 1701-1707
  • 39 Lok A S, Heathcote E J, Hoofnagle J H. Management of hepatitis B: 2000-summary of a workshop.  Gastroenterology . 2001;  120 1828-1853
  • 40 Sherman M, Peltekian K M, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population.  Hepatology . 1995;  22 432-437
  • 41 Sallie R. Screening for hepatocellular carcinoma in patients with chronic viral hepatitis: can the results justify the effort?.  Viral Hepat Rev . 1995;  1 77-95
  • 42 Tsai S L, Huang G T, Yang P M. Plasma des-gamma-carboxyprothrombin in the early stage of hepatocellular carcinoma.  Hepatology . 1990;  11 481-488
  • 43 Perrillo R P, Schiff E R, Davis G L. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B.  N Engl J Med . 1990;  323 295-301
  • 44 Wong D KH, Cheung A M, O'Rourke K. Effect of alpha interferon treatment in patients with hepatitis B e antigen positive chronic hepatitis B: a meta-analysis.  Ann Intern Med . 1993;  119 312-333
  • 45 Niederau C, Heinteges T, Lange S. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.  N Engl J Med . 1996;  334 1422-1427
  • 46 Lin S M, Sheen I S, Chien R N, Chu C M, Liaw Y F. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection.  Hepatology . 1999;  29 971-975
  • 47 Hoofnagle J H, DiBisceglie A M, Waggoner J G, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B.  Gastroenterology . 1993;  104 1116-1121
  • 48 Perrillo R, Tamburro C, Regenstein F. Low dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus.  Gastroenterology . 1995;  109 908-916
  • 49 Lai C L, Yuen M F, Hui C K. Comparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B: results of 24 weeks of therapy.  J Med Virol . 2002;  67 334-338
  • 50 Aye T T, Bartholomeusz A, Shaw T. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation.  J Hepatol . 1997;  26 1148-1153
  • 51 Berenguer M, Prieto M, Rayon M. Famciclovir treatment in transplant recipients with HBV-related liver disease: disappointing results.  Am J Gastroenterol . 2001;  96 526-533
  • 52 Singh N, Gayowski T, Wannstedt C F. Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation.  Transplantation . 1997;  63 1415-1419
  • 53 Gish R G, Lau J Y, Brooks L. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients.  Hepatology . 1996;  21 1-7
  • 54 Dienstag J, Schiff E R, Wright T L. Lamivudine as initial treatment for chronic hepatitis B in the United States.  N Engl J Med . 1999;  341 1256-1263
  • 55 Lai C, Chien R, Leung N WY. A one year trial of lamivudine for chronic hepatitis B.  N Engl J Med . 1998;  339 61-68
  • 56 Villeneuve J, Condreay L D, Willems B. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.  Hepatology . 2000;  31 207-210
  • 57 Yao F Y, Bass N M. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection.  J Hepatol . 2000;  33 301-307
  • 58 Yao F Y, Terrault N A, Freise C, Maslow L, Bass N M. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort.  Hepatology . 2001;  34 411-416
  • 59 Kapoor D, Guptan R C, Wakil S M. Beneficial effects of lamivudine in hepatitis B virus related decompensated cirrhosis.  J Hepatol . 2000;  33 308-312
  • 60 Kitay-Cohen Y, Ben-ari Z, Tur-Kaspa R, Fainguelernt H, Lishner M. Extension of transplantation free time by lamivudine in patients with hepatitis B induced decompensated cirrhosis.  Transplantation . 2000;  69 2382-2383
  • 61 Fontana R J, Keeffe E B, Carey W. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B.  Liver Transplant . 2002;  8 433-439
  • 62 Perrillo R P, Wright T, Rakela J. A multi-center United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.  Hepatology . 2001;  33 424-432
  • 63 Fontana R J, Hann H L, Perrillo R P. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy.  Gastroenterology . 2002;  123 719-727
  • 64 Fontana R J, Lok A SF. Lamivudine treatment in patients with decompensated hepatitis B cirrhosis: for whom and when?.  [editorial] Hepatology . 2000;  33 329-332
  • 65 Leung N WY, Lai C L, Chang T T. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.  Hepatology . 2001;  33 1527-1532
  • 66 Allen M I, Deslauriers M, Andrews W. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine.  Hepatology . 1998;  27 1670-1677
  • 67 Melegari M, Scaglioni P P, Wands J R. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective.  Hepatology . 1998;  27 628-633
  • 68 Liaw Y, Chien R, Yeh C, Tsai S, Chu C. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy.  Hepatology . 1999;  30 567-572
  • 69 Yeh C T, Chien R N, Chu C M, Liaw Y F. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy.  Hepatology . 2000;  31 1318-1326
  • 70 Lok A S, Hussain M, Cursano C. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen- negative patients receiving lamivudine therapy.  Hepatology . 2000;  32 1145-1153
  • 71 Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review.  Hepatology . 2000;  32 1189-1195
  • 72 Mutimer D, Pillay D, Dragon E. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft reinfection after liver transplantation.  J Hepatol . 1999;  30 715-721
  • 73 Han S H, Ofman J, Holt C. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.  Liver Transplant . 2000;  6 741-748
  • 74 Angus P W, McCaughan G W, Gane E J, Crawford D H, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B.  Liver Transplant . 2000;  6 429-433
  • 75 Yao F Y, Osorio R W, Roberts J P. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation.  Liver Transplant Surg . 1999;  5 491-496
  • 76 Locarnini S A. Hepatitis B virus surface antigen and polymerase gene variants: potential virological and clinical significance [editorial].  Hepatology . 1998;  27 294-297
  • 77 Saab S, Kim M, Wright T L. Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus.  Gastroenterology . 2000;  119 1382-1384
  • 78 Schiff E, Lai C L, Neuhaus P. Adefovir dipivoxil for the treatment of chronic hepatitis B in patients pre and post liver transplantation with lamivudine resistant hepatitis B virus patients (Abst).  Hepatology . 2002;  36 371A
  • 79 Rosenau J, Bahr M J, Tillmann H L. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation: possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection.  J Hepatol . 2001;  34 895-902
  • 80 Marcellin P, Goodman Z, Chang T T. Histological improvement in HBeAg positive chronic hepatitis B patients treated with adefovir dipivoxil (Abst).  J Hepatol . 2002;  36(Suppl 1) 8
  • 81 Hadiziyannis S, Tassopolous N, Heathcote E. A double-blind, randomized placebo-controlled study of adefovir dipivoxil for presumed precore mutant chronic hepatitis B: 48 week results (Abst).  J Hepatol . 2002;  36(Suppl 1) 4
  • 82 Perrillo R, Schiff E, Yoshida E. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.  Hepatology . 2000;  32 129-134
  • 83 Peters M, Schiff E, Benhamou Y. Adefovir dipivoxil demonstrates antiviral efficacy and clinical benefit in the treatment of lamivudine resistant chronic HBV: an analysis of four clinical trials (Abst).  Gastroenterology . 2002;  123(Suppl) 71
  • 84 Shakil A O, Lilly L, Angus P. Entecavir reduces viral load in liver transplant patients who failed prophylaxis or treatment for hepatitis B (Abst).  Hepatology . 2001;  34 619A
  • 85 DeMan R A, Wolters L MM, Nevens F. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection.  Hepatology . 2001;  34 578-582
  • 86 Levine S, Hernandez D, Yamanaka G. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.  Antimicrob Agents Chemother . 2002;  46 2525-2532
  • 87 James J S. Tenofovir approved: broad indication.  AIDS Treat News . 2001;  26 2-3
  • 88 Van Bommel F, Wunsche T, Schurmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication.  Hepatology . 2002;  36 507-508
  • 89 Chien R N, Liaw Y F, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion and continued ALT normalization in Asian patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group.  Hepatology . 1999;  30 770-774